ST. LOUIS & FOSTER CITY, Calif.--(BUSINESS WIRE)--
Partek Incorporated, a global leader in bioinformatics software, and Life Technologies, a maker of systems, consumables, and services that enable researchers to accelerate scientific and medical advancements, announced a partnership to allow users of Partek Flow, Partek Genomics Suite, and Partek Pathway a streamlined selection of Life Technologies TaqMan assays directly from the software user interface.
Parteks suite of software aids scientists in their analysis of their next generation sequencing and microarray data with powerful statistics and visualization tools.Real-time PCR forvalidation and further functional characterizationsis widely used downstream of these genomic experiments.TaqManprobebased chemistry is considered the gold standard for real time PCR. By adding a seamless connection from any of Parteks software lists of genes or regions of interestto the relevant TaqMan assays associated with those genesusers have the convenience of a relevant list of appropriate TaqMan assays, but more importantly they have increased accuracy by avoiding the manual, time consuming research required to choose the correct TaqMan assay. This direct interface is available for any list of genes or regions for any application including RNA-seq, transcriptome, miRNA, SNP genotyping, and copy number analysis. Were pleased to work together with our partner Life Technologies to combine two very widely used features by our common customers, saving them valuable time so they can focus on research instead of technical details, said Tom Downey, President of Partek.
Life Technologies has developed the most comprehensive set of real-time PCR assays available, with over 8 million predesigned assays covering 23 species for gene expression, microRNA, noncoding RNA, protein analysis, mutation detection, copy number variation, and SNP genotyping. The field of genetic analysis and next generation sequencing is moving at a fast pace and we are excited to offer researchers an integrated solution to help them advance their research, said Larry Milocco, Life Technologies.
About Partek
Partek Incorporated develops and globally markets quality software for life sciences research. Their software suitePartek Flow, Partek Genomics Suite, and Partek Pathwayprovides innovative solutions for integrated genomics and is unique in offering comprehensive support for all major next generation sequencing and microarray platforms. Workflows offer streamlined data analysis for: RNA-Seq, ChIP-Seq, DNA-Seq, DNA Methylation, Gene Expression, Alternative Splicing, miRNA Expression, Copy Number, Allele-Specific Copy Number, LOH, Association, Trio Analysis, Tiling, and qPCR. Since 1993, Partek has been turning data into discovery.
About Life Technologies
Life Technologies Corporation(NASDAQ: LIFE - News) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables, and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqManproducts. Life Technologies had sales of $3.7 billion in 2011, employs approximately 10,400 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 4,000 patents and exclusive licenses. For more information on how we are making a difference, please visit our website:www.lifetechnologies.com.
Safe Harbor Statement
Certain statements contained in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and Life Technologies intend that such forward-looking statements be subject to the safe harbor created thereby. Forward-looking statements may be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will," or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of the company. Such forward-looking statements include, but are not limited to, statements relating to financial projections, including revenue and pro forma EPS projections; success of acquired businesses, including cost and revenue synergies; development and increased flow of new products; leveraging technology and personnel; advanced opportunities and efficiencies; opportunities for growth; expectations of prospective new standards, new delivery platforms, and new selling specialization and effectiveness; and corporate strategy and performance. A number of the matters discussed in this press release and presentation that are not historical or current facts deal with potential future circumstances and developments, including future research and development plans. The discussion of such matters is qualified by the inherent risks and uncertainties surrounding future expectations generally and other factors that could cause actual results to differ materiallyfrom future results expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: volatility of the financial markets; and the risks that are described from time to time in Life Technologies' reports filed with the SEC. This press release and presentation speaks only as of its date, and the company disclaims any duty to update the information herein.
Originally posted here:
Partek and Life Technologies Partner to Speed Genetic Analysis Validation
Recommendation and review posted by G. Smith
